Myocarditis, COVID-19 and anti-sarscov2 vaccines in adolescents are we really reporting the truth about real-world adverse drug reactions?
Article Sidebar
Main Article Content
Abstract
in this editorial we will focus about epidemiology of myocarditis/pericarditis related to patients affected by COVID-19 disease or that underwent Anti-SarsCov2 vaccination. We will evaluate VAERS and EudraVigilance data about myocarditis/pericarditis and we will spot the differences between passive and active pharmacovigilance; moreover we will accurately evaluate the real risk/benefit ratio related to administration to adolescents of COVID-19 vaccination drugs.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
- Michael K; Jason A; StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. https://www.ncbi.nlm.nih.gov/books/NBK459259/
- Friman G, Wesslén L, Fohlman J, Karjalainen J, Rolf C. The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy. Eur Heart J. 1995 Dec;16 Suppl O:36-41. doi: 10.1093/eurheartj/16.suppl_o.36.
- Siripanthong B, Nazarian S, Muser D, Deo R, Santangeli P, Khanji M et al. Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020 Sep; 17(9): 1463–1471. doi: 10.1016/j.hrthm.2020.05.001
- Bozkurt B, Kamat I, Hotez P. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144:471–484. DOI: 10.1161/CIRCULATIONAHA.121.056135
- Kerneis M, Bihan K. Salem J. COVID-19 vaccines and myocarditis, Arch Cardiovasc Dis, https://doi.org/10.1016/j.acvd.2021.06.001
- Deb A, Abdelmalek J, Iwuji K, Nugent K. Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. Journal of Primary Care & Community Health, Volume 12: 1–5; https://doi.org/10.1177/21501327211029
- Muthukumar A, Narasimhan M, Li Q, Mahimainathan L, Hitto I, Fuda F. In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine. Circulation. 2021;144:487–498. DOI: 10.1161/CIRCULATIONAHA.121.056038
- Morbidity and Mortality Weekly Report US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / July 9, 2021 / Vol. 70 / No. 27 977 Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
- Muthukumar A, Narasimhan M, Li Q, Mahimainathan L, Hitto I, Fuda F. In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine. Circulation. 2021;144:487–498. DOI: 10.1161/CIRCULATIONAHA.121.056038
- Morbidity and Mortality Weekly Report US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / July 9, 2021 / Vol. 70 / No. 27 977 Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
- Jacqui W. Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines? BMJ 2021;373:n1635 http://dx.doi.org/10.1136/bmj.n1635
- Muthukumar A, Narasimhan M, Li Q, Mahimainathan L, Hitto I, Fuda F. In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine. Circulation. 2021;144:487–498. DOI: 10.1161/CIRCULATIONAHA.121.056038
- Morbidity and Mortality Weekly Report US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR / July 9, 2021 / Vol. 70 / No. 27 977 Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
- Jacqui W. Covid-19: Should we be worried about reports of myocarditis and pericarditis after mRNA vaccines? BMJ 2021;373:n1635 http://dx.doi.org/10.1136/bmj.n1635
- Levin A, Hanage W, Owusu Boaitey N, Cochran K, Walsh S, Meyerowitz Katz G.Assessing the age specifcity of infection fatality rates for COVID 19:systematic review, meta analysis, and public policy implications. European Journal of Epidemiology (2020) 35:1123–1138; https://doi.org/10.1007/s10654-020-00698-1
- R. Mei, et al., Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System, Int J Cardiol (2018), https://doi.org/10.1016/j.ijcard.2018.09.054
- Hazell L, Shakir S, Under-Reporting of Adverse Drug Reactions: A Systematic Review. Drug Safety 2006; 29 (5): 385-396 0114-5916/06/0005-0385
- Miller E, McNeil M, Moro P et al., The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome, Vaccine, https://doi.org/10.1016/j.vaccine.2020.09.072
- Bansal A, Agrawal A, Sharma L, Jain S. A Comparative Study of Active and Passive Adverse Drug Reaction Reporting Systems in Terms of False Reporting Rate Scr Med 2020;51(4):223-7. DOI:10.5937/scriptamed51-29065
- Liu Z, Meng R, Yang Y, Li K, Yin Z, Ren J. Active Vaccine Safety Surveillance: Global Trends and Challenges in China. Health Data Science Volume 2021, Article ID 9851067; https://doi.org/10.34133/2021/9851067
- Hause AM, Gee J, Baggs J, et al. COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021. MMWR Morb Mortal Wkly Rep 021;70:1053-1058. DOI: http://dx.doi.org/10.15585/mmwr.mm7031e1external icon
- Cevik M, Tate M, Lloyd O, Maraolo A, Schafers A, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe 2021; 2: e13–22 Published Online November 19, 2020 https://doi.org/10.1016/ S2666-5247(20)30172-5
- Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A et al. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. doi: https://doi.org/10.1101/2021.08.24.21262415